Literature DB >> 20440848

Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-beta signaling.

Suntaek Hong1, Ho-Jae Lee, Seong Jin Kim, Ki-Baik Hahm.   

Abstract

Inflammation is a primary defense process against various extracellular stimuli, such as viruses, pathogens, foods, and environmental pollutants. When cells respond to stimuli for short periods of time, it results in acute or physiological inflammation. However, if the stimulation is sustained for longer time or a pathological state occurs, it is known as chronic or pathological inflammation. Several studies have shown that tumorigenesis in the gastrointestinal (GI) tract is closely associated with chronic inflammation, for which abnormal cellular alterations that accompany chronic inflammation such as oxidative stresses, gene mutations, epigenetic changes, and inflammatory cytokines, are shared with carcinogenic processes, which forms a critical cross-link between chronic inflammation and carcinogenesis. Transforming growth factor (TGF)-beta is a multi-potent cytokine that plays an important role in regulation of cell growth, apoptosis and differentiation. Most importantly, TGF-beta is a strong anti-inflammatory cytokine that regulates the development of effector cells. TGF-beta has a suppressive effect on carcinogenesis under normal conditions by inhibiting abnormal cell growth, but on the other hand, many GI cancers originate from uncontrolled cell growth and differentiation by genetic loss of TGF-beta signaling molecules or perturbation of TGF-beta adaptors. Once a tumor has developed, TGF-beta exerts a promoting effect on the tumor itself and stromal cells to enhance cell growth, alter the responsiveness of tumor cells to stimulate invasion and metastasis, and inhibited immune surveillance. Therefore, novel development of therapeutic agents to inhibit TGF-beta-induced progression of tumor and to retain its growth inhibitory activities, in addition to anti-inflammatory actions, could be useful in oncology. In this review, we discuss the role of TGF-beta in inflammation and carcinogenesis of the GI tract related to abnormal TGF-beta signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20440848      PMCID: PMC2864833          DOI: 10.3748/wjg.v16.i17.2080

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  97 in total

1.  Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis.

Authors:  Melissa A Rowland-Goldsmith; Haruhisa Maruyama; Kei Matsuda; Takenao Idezawa; Monica Ralli; Sonia Ralli; Murray Korc
Journal:  Mol Cancer Ther       Date:  2002-01       Impact factor: 6.261

Review 2.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

Review 3.  The two faces of transforming growth factor beta in carcinogenesis.

Authors:  Anita B Roberts; Lalage M Wakefield
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-14       Impact factor: 11.205

4.  Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling.

Authors:  Nanjoo Suh; Anita B Roberts; Stephanie Birkey Reffey; Kohei Miyazono; Susumu Itoh; Peter ten Dijke; Elke H Heiss; Andrew E Place; Renee Risingsong; Charlotte R Williams; Tadashi Honda; Gordon W Gribble; Michael B Sporn
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

5.  Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery.

Authors:  Anna L Mead; Tina T L Wong; M Francesca Cordeiro; Ian K Anderson; Peng T Khaw
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-08       Impact factor: 4.799

Review 6.  Hallmarks of cancer progression in Barrett's oesophagus.

Authors:  Carmela P Morales; Rhonda F Souza; Stuart J Spechler
Journal:  Lancet       Date:  2002-11-16       Impact factor: 79.321

7.  Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.

Authors:  Rebecca S Muraoka; Nancy Dumont; Christoph A Ritter; Teresa C Dugger; Dana M Brantley; Jin Chen; Evangeline Easterly; L Renee Roebuck; Sarah Ryan; Philip J Gotwals; Victor Koteliansky; Carlos L Arteaga
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

8.  Oral administration of specific antigens to allergy-prone infant dogs induces IL-10 and TGF-beta expression and prevents allergy in adult life.

Authors:  Barbara Zemann; Christoph Schwaerzler; Monika Griot-Wenk; Marijke Nefzger; Peter Mayer; Heinz Schneider; Alain de Weck; José M Carballido; Ekke Liehl
Journal:  J Allergy Clin Immunol       Date:  2003-05       Impact factor: 10.793

9.  Transforming growth factor beta mimetics: discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase.

Authors:  Keith B Glaser; Junling Li; Mary E Aakre; Douglas W Morgan; George Sheppard; Kent D Stewart; Jennifer Pollock; Paul Lee; Chad Z O'Connor; Steven N Anderson; Donna J Mussatto; Craig W Wegner; Harold L Moses
Journal:  Mol Cancer Ther       Date:  2002-08       Impact factor: 6.261

10.  Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.

Authors:  Abhik Bandyopadhyay; Fernando López-Casillas; Shazli N Malik; José Luis Montiel; Valentín Mendoza; Junhua Yang; L-Z Sun
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

View more
  37 in total

1.  Squamous cell carcinoma arising from long-standing perianal fistula.

Authors:  K Chandramohan; Arun Peter Mathew; Madhu Muralee; K R Anila; K Ramachandran; Iqbal Ahamed
Journal:  Int Wound J       Date:  2010-08-19       Impact factor: 3.315

2.  Vasohibin-1 expression is regulated by transforming growth factor-β/bone morphogenic protein signaling pathway between tumor-associated macrophages and pancreatic cancer cells.

Authors:  Zhanlong Shen; Hanna Seppänen; Tuuli Kauttu; Sanna Vainionpää; Yingjiang Ye; Shan Wang; Harri Mustonen; Pauli Puolakkainen
Journal:  J Interferon Cytokine Res       Date:  2013-05-07       Impact factor: 2.607

3.  Common colorectal cancer risk variants in SMAD7 are associated with survival among prediagnostic nonsteroidal anti-inflammatory drug users: a population-based study of postmenopausal women.

Authors:  Michael N Passarelli; Anna E Coghill; Carolyn M Hutter; Yingye Zheng; Karen W Makar; John D Potter; Polly A Newcomb
Journal:  Genes Chromosomes Cancer       Date:  2011-08-24       Impact factor: 5.006

Review 4.  From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.

Authors:  Ravindran Caspa Gokulan; Monica T Garcia-Buitrago; Alexander I Zaika
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

Review 5.  Single Nucleotide Polymorphism in SMAD7 and CHI3L1 and Colorectal Cancer Risk.

Authors:  Amal Ahmed Abd El-Fattah; Nermin Abdel Hamid Sadik; Olfat Gamil Shaker; Amal Mohamed Kamal
Journal:  Mediators Inflamm       Date:  2018-10-25       Impact factor: 4.711

6.  The density of macrophages in colorectal cancer is inversely correlated to TGF-β1 expression and patients' survival.

Authors:  Maya Gulubova; Julian Ananiev; Yovchev Yovchev; Aleksander Julianov; Anatoli Karashmalakov; Tatyana Vlaykova
Journal:  J Mol Histol       Date:  2013-06-26       Impact factor: 2.611

7.  TGF-β/SMAD3 Pathway Stimulates Sphingosine-1 Phosphate Receptor 3 Expression: IMPLICATION OF SPHINGOSINE-1 PHOSPHATE RECEPTOR 3 IN LUNG ADENOCARCINOMA PROGRESSION.

Authors:  Jiawei Zhao; Jingjing Liu; Jen-Fu Lee; Wenliang Zhang; Mustapha Kandouz; Garrett C VanHecke; Shiyou Chen; Young-Hoon Ahn; Fulvio Lonardo; Menq-Jer Lee
Journal:  J Biol Chem       Date:  2016-11-17       Impact factor: 5.157

8.  Genetic variation in the transforming growth factor-β signaling pathway and survival after diagnosis with colon and rectal cancer.

Authors:  Martha L Slattery; Abbie Lundgreen; Jennifer S Herrick; Roger K Wolff; Bette J Caan
Journal:  Cancer       Date:  2011-03-01       Impact factor: 6.860

9.  Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.

Authors:  Yanxia Zhao; Jinghong Cao; Alexander Melamed; Michael Worley; Allison Gockley; Dennis Jones; Hadi T Nia; Yanling Zhang; Triantafyllos Stylianopoulos; Ashwin S Kumar; Fotios Mpekris; Meenal Datta; Yao Sun; Limeng Wu; Xing Gao; Oladapo Yeku; Marcela G Del Carmen; David R Spriggs; Rakesh K Jain; Lei Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-18       Impact factor: 11.205

10.  Increased expression of DLX2 correlates with advanced stage of gastric adenocarcinoma.

Authors:  Peng Tang; Hua Huang; Jiang Chang; Gong-Fang Zhao; Ming-Liang Lu; Yan Wang
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.